Holen Sie sich die Stockscreener-App
0.6644
5.00%
-0.035
Handel nachbörslich:
.67
0.0056
+0.84%
Schlusskurs vom Vortag:
$0.6994
Offen:
$0.671
24-Stunden-Volumen:
598.72K
Relative Volume:
0.61
Marktkapitalisierung:
$39.01M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-123.46M
KGV:
-0.2565
EPS:
-2.59
Netto-Cashflow:
$-104.11M
1W Leistung:
-5.99%
1M Leistung:
-4.24%
6M Leistung:
+19.07%
1J Leistung:
-68.21%
1-Tages-Spanne:
$0.6501
$0.72
1-Wochen-Bereich:
$0.6501
$0.7579
52-Wochen-Spanne:
$0.2601
$2.525
Bioatla Inc Stock (BCAB) Company Profile
Firmenname
Bioatla Inc
Sektor
Branche
Telefon
858-558-0708
Adresse
11085 TORREYANA ROAD, SAN DIEGO
Vergleichen Sie BCAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.6644 | 41.07M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-13 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-05-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | BTIG Research | Buy |
| 2021-01-11 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-01-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Bioatla Inc Aktie (BCAB) Neueste Nachrichten
Is BioAtla Inc. a candidate for recovery playPortfolio Growth Summary & Weekly Chart Analysis and Trade Guides - newser.com
Analyzing BioAtla Inc. with multi timeframe chartsEarnings Risk Summary & Daily Technical Forecast Reports - newser.com
Why BioAtla Inc. stock is favored by top institutions2025 Technical Patterns & High Yield Stock Recommendations - newser.com
Analyzing BioAtla Inc. with risk reward ratio chartsJuly 2025 Pullbacks & Reliable Breakout Forecasts - newser.com
Sentiment analysis tools applied to BioAtla Inc.Quarterly Profit Summary & Weekly Top Performers Watchlists - newser.com
Regression analysis insights on BioAtla Inc. performanceEarnings Growth Report & Safe Capital Growth Tips - newser.com
Measuring BioAtla Inc.’s beta against major indicesJuly 2025 Patterns & Intraday High Probability Setup Alerts - newser.com
What to do if you’re stuck in BioAtla Inc.July 2025 Review & Technical Pattern Recognition Alerts - newser.com
BioAtla, Inc. (BCAB) stock forecast and price target - Yahoo! Finance UK
How supply chain issues affect BioAtla Inc. stockJuly 2025 Spike Watch & Weekly Market Pulse Alerts - newser.com
Will BioAtla Inc. continue its uptrend2025 Earnings Surprises & Stepwise Entry and Exit Trade Signals - newser.com
Chart overlay techniques for tracking BioAtla Inc.Quarterly Growth Report & Stock Timing and Entry Methods - newser.com
BioAtla, Inc. (BCAB) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
What moving averages say about BioAtla Inc.Bond Market & Capital Efficiency Focused Ideas - newser.com
BioAtla’s Phase 1 Study on BA3182: A New Hope for Advanced Adenocarcinoma - MSN
BioAtla (BCAB) to Release Quarterly Earnings on Thursday - Defense World
BioAtla Stock Lost 7.0%, Buy Or Wait? - Trefis
Why BioAtla Inc. stock is a value investor pickWeekly Risk Summary & Advanced Technical Signal Analysis - fcp.pa.gov.br
Finanzdaten der Bioatla Inc-Aktie (BCAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):